BioCryst Pharmaceuticals, Inc. (BCRX) Investor Relations Documents

BioCryst Pharmaceuticals, Inc. (BCRX) investor relations documents from the company's IR site: 6 presentations, 34 press releases; latest deck 2026-02-26. Read in-app with summaries. First-party data.

Q4 2025 Earnings Presentation Slides — BioCryst Full Year 2025 results report $563M in non-GAAP ORLADEYO revenue and outline a strategic path to $1B peak revenue by 2029.

Investor relations documents — source: company IR site
PublishedTypeDocument
2026-08-05Press releaseBioCryst Reports Second Quarter 2026 Financial Results
2026-07-22Press releaseBioCryst to Report Second Quarter 2026 Financial Results on August 5
2026-07-15Press releaseBioCryst Appoints David W. Jenkins as Chief Scientific Officer
2026-07-02Press releaseBioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-06-29Press releaseBioCryst Sharpens Scientific Focus on External Innovation with Wind Down of Internal Discovery Programs and Closure of B
2026-06-12Press releaseBioCryst Presents New Clinical Data and Real-World Evidence Demonstrating Impact of HAE Portfolio at the 2026 European A
2026-06-09Press releaseBioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-05-27Press releaseBioCryst to Present New HAE Data from ORLADEYO® (berotralstat) and Navenibart at the 2026 European Academy of Allergy an
2026-05-13Press releaseBioCryst to Present New Real-World Evidence Underscoring the Ongoing Burden of Pediatric Hereditary Angioedema at ISPOR
2026-05-06Press releaseBioCryst Reports First Quarter 2026 Financial Results and Provides Business Update
2026-02-26Earnings deckQ4 2025 Earnings Presentation Slides
2026-02-26Press releaseBioCryst Reports Full Year 2025 Financial Results and Provides Business Update
2026-02-17Press releaseBioCryst to Present at Upcoming Investor Conference
2026-02-11Press releaseBioCryst to Present New HAE Data from ORLADEYO® (berotralstat) and Navenibart at the 2026 American Academy of Allergy, A
2026-02-05Press releaseBioCryst to Report Fourth Quarter 2025 Financial Results on February 26
2026-01-23Press releaseBioCryst Completes Acquisition of Astria Therapeutics, Expanding Leadership in Hereditary Angioedema
2026-01-12Press releaseBioCryst Announces Preliminary Full Year 2025 ORLADEYO® (berotralstat) Net Revenue of $601 Million (+37 percent y-o-y),
2026-01-06Press releaseBioCryst to Present at 44th Annual J.P. Morgan Healthcare Conference
2025-02-24Press releaseBioCryst Reports Fourth Quarter and Full Year 2024 Financial Results and Upcoming Key Milestones
2024-11-04Press releaseBioCryst Reports Third Quarter 2024 Financial Results and Provides Business Update
2024-08-05Press releaseBioCryst Reports Second Quarter 2024 Financial Results and Provides Business Update
2024-05-06Press releaseBioCryst Reports First Quarter 2024 Financial Results and Provides Business Update
2024-02-26Press releaseBioCryst Reports Fourth Quarter and Full Year 2023 Financial Results and Upcoming Key Milestones
2023-11-02Press releaseBioCryst Reports Third Quarter 2023 Financial Results and Provides Business Update
2023-08-03Press releaseBioCryst Reports Second Quarter 2023 Financial Results and Provides Business Update
2023-05-03Earnings deckQ1 2023 Earnings Presentation Slides
2023-05-03Press releaseBioCryst Reports First Quarter 2023 Financial Results and Provides Business Update
2023-02-21Press releaseBioCryst Reports Fourth Quarter and Full Year 2022 Financial Results and Upcoming Key Milestones
2022-11-01Press releaseBioCryst Reports Third Quarter 2022 Financial Results and Upcoming Key Milestones
2022-08-31Press releasePress release
2022-08-04Press releaseBioCryst Reports Second Quarter 2022 Financial Results and Upcoming Key Milestones
2022-07-15Press releasePress release
2022-05-05Press releaseBioCryst Reports First Quarter 2022 Financial Results and Upcoming Key Milestones
2022-02-23Earnings deckQ4 2021 Earnings Presentation Slides
2022-02-23Press releaseBioCryst Reports Fourth Quarter and Full Year 2021 Financial Results and Upcoming Key Milestones
2021-11-03Earnings deckQ3 2021 Earnings Presentation Slides
2021-11-03Press releaseBioCryst Reports Third Quarter 2021 Financial Results and Upcoming Key Milestones
2021-08-05Earnings deckQ2 2021 Earnings Presentation Slides
2021-08-05Press releaseBioCryst Reports Second Quarter 2021 Financial Results and Upcoming Key Milestones
2021-05-06Earnings deckQ1 2021 Earnings Presentation Slides

BCRX overview · BCRX earnings · BCRX financials · BCRX KPIs · BCRX ownership · BCRX peers · BCRX filings

Documents published by the company on its investor-relations site; summaries are model-written. Not personalized investment advice.